Loading
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Regular session
$2.535
−$0.015 · -0.59%
Regular session · ET · Market data may be delayed.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Day range
Current $2.535
52-week range
Current $2.535
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
23
Expensive
Sentiment
43
Mixed
Risk
72
High Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Day range
Current $2.535
52-week range
Current $2.535
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CHF) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.57M CHF | 27.31M CHF | 14.8M CHF | 3.94M CHF | — |
| Cost of goods sold | — | 62.57M CHF | 54.61M CHF | — | — |
| Gross profit | 3.57M CHF | −35.26M CHF | −39.81M CHF | 3.94M CHF | — |
| Research and development | 56.44M CHF | 62.57M CHF | 54.61M CHF | 60.34M CHF | 62.28M CHF |
| Selling, general, and administrative | 11.65M CHF | 11.43M CHF | 10.58M CHF | 9.58M CHF | 10.88M CHF |
| Operating expenses | 72.44M CHF | 17.12M CHF | 13.82M CHF | 74.78M CHF | 79.01M CHF |
| Interest income | 1.87M CHF | 3.2M CHF | 1.04M CHF | 69K CHF | 6.49M CHF |
| Interest expense | 191K CHF | 133K CHF | 176K CHF | 355K CHF | 581K CHF |
| Depreciation and amortization | 2.5M CHF | 2.16M CHF | 2.22M CHF | 2.36M CHF | 2.41M CHF |
| Operating income | −68.86M CHF | −52.38M CHF | −53.62M CHF | −70.85M CHF | −79.01M CHF |
| Net income | −70.45M CHF | −50.92M CHF | −54.23M CHF | −70.75M CHF | −73M CHF |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.33
228.60% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB1.21M0.01%10.41B USD0.44%$204.61+2.06%
Dimensional - US Small Cap ETFDFAS324.15K0.00%33.8B USD0.31%$78.33+0.29%
U.S. Micro Cap Portfolio ETFDFMC113.27K0.00%7.54B USD0.43%$57.83+0.23%
U.S. Vector Equity Portfolio ETF Class SharesDXUV40.66K0.00%6.17B USD0.26%$68.22+0.16%
Dimensional - US Core Equity 2 ETFDFAC20.21K0.00%88.2B USD0.21%$45.255+0.32%
Invesco Nasdaq Biotechnology ETFIBBQ19.35K0.02%109.47M USD0.19%$34.275+1.93%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR14.77K0.00%45.38B USD0.17%$84.24+0.20%
ProShares Ultra Nasdaq BiotechnologyBIB9.14K0.01%88.27M USD1.19%$109.03+3.81%iShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACInvesco Nasdaq Biotechnology ETFIBBQU.S. Core Equity 1 Portfolio ETF Class SharesDCORProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
